{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:46:26Z","timestamp":1783781186864,"version":"3.55.0"},"reference-count":33,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Nagoya University, Center for Advanced Medicine and Clinical Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Chugai Pharmaceutical Co., Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,12,23]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>For persons with haemophilia A with factor (F) VIII inhibitors (PwHAwI), immune tolerance induction (ITI) therapy is indicated for inhibitor eradication; however, since PwHAwI on ITI were excluded from the emicizumab clinical development programme, there are limited safety data for emicizumab treatment under\/immediately after ITI in PwHAwI. Accordingly, there is a need to collect safety and efficacy data on this concomitant treatment strategy. The AKATSUKI study aims to evaluate the safety of emicizumab under\/immediately after ITI in PwHAwI; here we report details of the study protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>AKATSUKI is an open-label, non-randomised, interventional, multicentre study. Twenty participants with congenital HA with FVIII inhibitors will be enrolled from 17 sites across Japan. Emicizumab will be administered subcutaneously, with an initial loading dose of 3\u2009mg\/kg once per week (QW) for the first 4\u2009weeks, followed by a maintenance dose of 1.5\u2009mg\/kg QW, 3\u2009mg\/kg once every 2 weeks or 6\u2009mg\/kg once every 4 weeks. For ITI therapy, 50\u2009IU\/kg FVIII will be administered three times per week. For extended half-life FVIII, a dosing frequency of twice per week will be permitted. The primary endpoint is a comprehensive safety evaluation of adverse events (mainly thromboembolic events) and abnormal laboratory values over time. Secondary endpoints are the number of bleeds requiring coagulation factor treatment, the number of participants achieving a partially successful ITI response, FVIII inhibitor titres under\/immediately after ITI, quality of life and time to achieve a negative FVIII inhibitor result (&lt;0.6 BU\/mL) and partial success in PwHAwI starting ITI after study enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:bold>A<\/jats:bold>\n                      KATSUKI will evaluate the safety of emicizumab administered under\/immediately after ITI, providing reference data to inform treatment strategies in PwHAwI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      The results of this study will be published in a peer-reviewed international journal and presented at national and\/or international medical scientific conferences; the major findings of this study will be published on the jRCT registry website (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\">https:\/\/jrct.niph.go.jp<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCTs041200037.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057018","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T12:02:00Z","timestamp":1647259320000},"page":"e057018","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors"],"prefix":"10.1136","volume":"12","author":[{"given":"Tadashi","family":"Matsushita","sequence":"first","affiliation":[{"name":"Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[{"name":"Ogikubo Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiai","family":"Nagae","sequence":"additional","affiliation":[{"name":"St Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Yamaguchi-Suita","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Kyogoku","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ioka","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2025120601082574000_12.3.e057018.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"2025120601082574000_12.3.e057018.2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"},{"key":"2025120601082574000_12.3.e057018.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2006.01359.x","article-title":"Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference","volume":"12","author":"Berntorp","year":"2006","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/hae.12379","article-title":"Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States","volume":"20","author":"DeKoven","year":"2014","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/hae.12501","article-title":"Impact of haemophilia with inhibitors on caregiver burden in the United States","volume":"20","author":"DeKoven","year":"2014","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: what have we learned over time?","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.7","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2025120601082574000_12.3.e057018.8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev"},{"key":"2025120601082574000_12.3.e057018.9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1365-2516.2009.01999.x","article-title":"Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs","volume":"15","author":"Santagostino","year":"2009","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.10","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/hae.13531","article-title":"The Japanese immune tolerance induction (J-ITI) study in haemophilia patients with inhibitor: outcomes and successful predictors of ITI treatment","volume":"24","author":"Nogami","year":"2018","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-369132"},{"key":"2025120601082574000_12.3.e057018.12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"2025120601082574000_12.3.e057018.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"2025120601082574000_12.3.e057018.14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cpdd.617","article-title":"Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers","volume":"8","author":"Kotani","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025120601082574000_12.3.e057018.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"2025120601082574000_12.3.e057018.16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17474086.2018.1531701","article-title":"Emicizumab for hemophilia A with factor VIII inhibitors","volume":"11","author":"Young","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"2025120601082574000_12.3.e057018.17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120601082574000_12.3.e057018.18","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025120601082574000_12.3.e057018.19","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"2025120601082574000_12.3.e057018.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"2025120601082574000_12.3.e057018.21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"2025120601082574000_12.3.e057018.22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4\u00a0weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17474086.2021.1875817","article-title":"Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors","volume":"14","author":"Carcao","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"2025120601082574000_12.3.e057018.24","first-page":"93","article-title":"JSTH guideline on the treatment of hemophilia: 2019 addendum on the use of Hemlibra (Emicizumab)","volume":"31","year":"2019","journal-title":"Jpn J Thromb Hemost"},{"key":"2025120601082574000_12.3.e057018.25","unstructured":"Pharmaceutical and Medical Devices Agency . Hemlibra prescribing information. Available: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6343451 [Accessed Dec 2021]."},{"key":"2025120601082574000_12.3.e057018.26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2491\/jjsth.24.640","article-title":"Japanese guideline for the hemostatic therapy of patients with congenital hemophilia and inhibitors (revised 2013)","volume":"24","year":"2013","journal-title":"Jpn J Thromb Hemost"},{"key":"2025120601082574000_12.3.e057018.27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2025120601082574000_12.3.e057018.29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"Batsuli","year":"2019","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.30","unstructured":"The hemophilia inhibitor eradication trial. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303572 [Accessed Dec 2021]."},{"key":"2025120601082574000_12.3.e057018.31","unstructured":"Emicizumab PUPs and Nuwiq ITI study. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04030052 [Accessed Dec 2021]."},{"key":"2025120601082574000_12.3.e057018.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"DiMichele","year":"2007","journal-title":"Haemophilia"},{"key":"2025120601082574000_12.3.e057018.33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:08:38Z","timestamp":1765012118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,14]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bmjopen-2021-057018"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057018","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}